Technical Analysis for MRSN - Mersana Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
MRSN closed down 1.4 percent on Wednesday, January 17, 2018, on 2.19 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||N/A||Down||Down|
|See historical MRSN trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||Shooting Star Candlestick||Bearish||0.00%|
|Jan 17||Slingshot Bearish||Bearish Swing Setup||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Oversold Stochastic||Weakness||0.00%|
|Jan 16||Stochastic Buy Signal||Bullish||-1.40%|
|Jan 16||Volume Surge||Other||-1.40%|
|Jan 16||Doji - Bullish?||Reversal||-1.40%|
|Jan 16||Wide Bands||Range Expansion||-1.40%|
|Jan 16||Lower Bollinger Band Touch||Weakness||-1.40%|
|Jan 16||Oversold Stochastic||Weakness||-1.40%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more MRSN news...
|52 Week High||21.01|
|52 Week Low||12.71|
|200-Day Moving Average||0.0|
|50-Day Moving Average||17.1468|
|20-Day Moving Average||16.6595|
|10-Day Moving Average||16.182|
|Average True Range||1.3082|
|Chandelier Exit (Long, 3 ATRs )||15.7654|
|Chandelier Exit (Short, 3 ATRs )||18.5146|
|Upper Bollinger Band||18.3309|
|Lower Bollinger Band||14.9881|
|Percent B (%b)||0.14|
|MACD Signal Line||-0.2874|
|Market Cap||350.69 Million|
|Num Shares||22.7 Million|
|Price-to-Earnings (P/E) Ratio||-0.95|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||17.21|
|Resistance 3 (R3)||17.33||16.87||16.92|
|Resistance 2 (R2)||16.87||16.42||16.81||16.82|
|Resistance 1 (R1)||16.15||16.14||15.92||16.03||16.72|
|Support 1 (S1)||14.97||15.24||14.74||14.85||14.16|
|Support 2 (S2)||14.51||14.96||14.45||14.06|
|Support 3 (S3)||13.79||14.51||13.97|
|Support 4 (S4)||13.67|